Pulmonx Co. (NASDAQ:LUNG - Get Free Report) CEO Steven S. Williamson sold 9,923 shares of Pulmonx stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $3.13, for a total value of $31,058.99. Following the completion of the sale, the chief executive officer now directly owns 366,115 shares of the company's stock, valued at $1,145,939.95. This trade represents a 2.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Pulmonx Trading Down 3.1%
Shares of Pulmonx stock traded down $0.10 during trading on Wednesday, reaching $3.08. 249,343 shares of the company were exchanged, compared to its average volume of 312,447. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. Pulmonx Co. has a twelve month low of $2.83 and a twelve month high of $9.37. The business has a 50-day moving average price of $4.49 and a 200-day moving average price of $6.01. The firm has a market capitalization of $123.99 million, a price-to-earnings ratio of -2.14 and a beta of 0.52.
Pulmonx (NASDAQ:LUNG - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.01. The firm had revenue of $22.54 million for the quarter, compared to analyst estimates of $22.03 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. Sell-side analysts anticipate that Pulmonx Co. will post -1.55 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have recently commented on LUNG. D. Boral Capital reissued a "buy" rating and issued a $17.00 target price on shares of Pulmonx in a research note on Thursday, May 1st. Citigroup lowered their target price on Pulmonx from $6.50 to $4.15 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Morgan Stanley began coverage on Pulmonx in a research note on Monday, March 10th. They set an "equal weight" rating for the company. Canaccord Genuity Group decreased their price objective on Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $9.00 price objective (down from $10.00) on shares of Pulmonx in a research note on Thursday, May 1st. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $11.59.
View Our Latest Stock Report on LUNG
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in LUNG. Deerfield Management Company L.P. Series C bought a new position in Pulmonx during the fourth quarter worth about $10,421,000. Parkman Healthcare Partners LLC lifted its holdings in Pulmonx by 194.4% during the first quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company's stock worth $4,118,000 after acquiring an additional 404,022 shares in the last quarter. Altium Capital Management LLC lifted its holdings in Pulmonx by 63.0% during the fourth quarter. Altium Capital Management LLC now owns 815,000 shares of the company's stock worth $5,534,000 after acquiring an additional 315,000 shares in the last quarter. Essex Investment Management Co. LLC bought a new position in Pulmonx during the first quarter worth about $2,041,000. Finally, Nuveen LLC bought a new position in Pulmonx during the first quarter worth about $1,336,000. 91.04% of the stock is currently owned by institutional investors.
Pulmonx Company Profile
(
Get Free Report)
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pulmonx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulmonx wasn't on the list.
While Pulmonx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
